復星醫藥(02196.HK)斥4.1億人幣增持杏脈科技 股權增至約73%
復星醫藥(02196.HK)(600196.SH)公布,復星醫藥產業、第三方國藥中金及安亭實業擬分別現金出資5,000萬元人民幣(下同)認繳杏脈科技新增註冊資本664萬元,即杏脈科技註冊資本合計增加1,992萬元。杏脈科技為公司控股股東復星高科技聯繫人。
另外,復星醫藥產業同意以3.6億元向復星高科技之附屬亞東智健收購杏脈科技註冊資本5,500萬元人民幣。
於增資及股權轉讓完成後,復星醫藥產業持有的杏脈科技股權比例將由約25.8824%增至約70.6502%,公司透過復星醫藥產業及佛山禪醫合共持有的杏脈科技股權比例將由約28.2353%增至約72.6316%,而杏脈科技將成為公司的附屬公司。
杏脈科技是一間專注於研發、生產、銷售醫療影像及病理人工智能軟件及數字化解決方案的科創型企業,部分產品已於2021年、2022年陸續進入商業化階段。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.